Sistema de Salut de Catalunya
Institut Català de la Salut
[Nozawa K] Department of Advanced Clinical Research and Development, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. Department of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. [Sawaki M] Department of Breast Oncology, Nagoya Medical Center, Nagoya, Japan. [Uemura Y] Biostatistics Section, Department of Data Science, Center of Clinical Sciences, National Center for Global Health and Medicine, Shinjuku, Japan. [Tsuneizumi M] Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan. [Takano T] Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Koto, Japan. [Gondo N] Department of Breast and Thyroid Surgical Oncology, Sagara Hospital, Kagoshima, Japan. [Villacampa G] Statistics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2026-03-03T13:22:24Z
2026-03-03T13:22:24Z
2025-11-04
Older patients; HER2-positive breast cancer; Chemotherapy
Pacientes mayores; Cáncer de mama HER2 positivo; Quimioterapia
Pacients grans; Càncer de mama HER2 positiu; Quimioteràpia
Older adults with HER2-positive early breast cancer are underrepresented in clinical trials, and the benefit of chemotherapy in this population remains uncertain. We evaluated the HER2DX genomic assay within the randomized RESPECT trial (NCT01104935), which compared adjuvant trastuzumab with or without chemotherapy in patients aged 70–80 years. In this prespecified translational analysis (Trans-RESPECT), HER2DX scores were available for 154 patients. The HER2DX risk score classified 74.0% as low risk and 26.0% as high risk. Ten-year relapse-free and overall survival were higher in the low-risk group. HER2DX remained independently associated with overall survival in multivariable analysis. The HER2DX immune, luminal, and proliferation signatures that compose the risk score were also prognostic. While the HER2DX pCR score was not prognostic overall, exploratory subgroup analyses suggested a potential survival benefit from chemotherapy in the pCR-high group. HER2DX offers prognostic value and may guide chemotherapy use in older patients with HER2-positive early breast cancer. Clinical Trial Information NCT01104935
This study was funded by CSPOR, Chugai Pharmaceutical Co. Ltd and Reveal Genomics.
Artículo
Versión publicada
Inglés
Persones grans; Quimioteràpia combinada; Mama - Càncer - Quimioteràpia; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; NAMED GROUPS::Persons::Age Groups::Adult::Aged; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; DENOMINACIONES DE GRUPOS::personas::Grupos de Edad::adulto::anciano; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
Nature communications
Nature Communications;16
https://doi.org/10.1038/s41467-025-65599-x
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
